Relma-cel Clinical Trials

2 actively recruiting trials

Also known as: CD19-targeted Chimeric Antigen Receptor(CAR) T Cells, JWCAR029

Pipeline

Phase 2: 1Phase 4: 1

Top Sponsors

Shanghai Ming Ju Biotechnology Co., Ltd.1
Ruijin Hospital1

Indications

Cancer2
Relapsed or Refractory B-cell Lymphoma1
Large B-cell Lymphoma1
Non-hodgkin Lymphoma1

Other2 trials

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Phase 2

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.